

# Primary Sclerosing Cholangitis and Cholestatic liver diseases

Ahsan M Bhatti MD, FACP

Bhatti Gastroenterology Consultants



**Bhatti GI**  
CONSULTANTS, P.A.

**I have nothing to disclose**



**Bhatti GI**  
CONSULTANTS, P.A.

# Educational Objectives

- What is PSC?
- Understand the cholestatic liver diseases
  - Signs, symptoms, blood work, imaging and diagnosis
- Management plan and long term follow up.
- Appreciate conditions associated with PSC.
- Difference in PSC and PBC



# Case Introduction

- 35 year old male referred for jaundice, itching, fatigue and weakness.
- Patient has h/o diarrhea and rectal bleeding off and on for a year. Recent diagnosis of Ulcerative colitis.
- F/H of Ulcerative colitis.
- H/O Iron deficiency anemia
- On mesalamine and MVI. H/O iron supplement.



**Bhatti GI**  
CONSULTANTS, P.A.

# Hepatocellular vs cholestatic liver Disease

- Hepatocellular liver disease is due to damage to hepatocytes.
  - Increase in ALT and AST.
- Cholestatic liver disease due to disease of Bile ducts and process where Bile acid flow is restricted.
  - Increase in ALP and GGT.




# PSC

- PSC is an idiopathic condition defined as the presence of beading and stricture formation of the intra and/or extrahepatic bile ducts that cannot be ascribed to another cause.
- PSC is characterized by inflammation, fibrosis, and stricturing of medium and large ducts in the intrahepatic and/or extrahepatic biliary tree
- Many, if not most, cases of PSC are associated with inflammatory bowel disease (IBD) up to 75%
- 12-15% will develop cholangiocarcinoma over life time.
- Male to female ratio is 2:1



# PSC

- Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver and biliary tract disease that has a highly variable natural history.
- Pathogenesis is not understood. Disease symptoms and complications are due to fibrosis and strictures of CBD.
- PSC may be asymptomatic for long periods but may also have an aggressive course, leading to recurrent biliary tract obstruction, recurrent episodes of cholangitis, and may progress to end-stage liver disease.
- The typical cholangiography findings include focal stricturing and saccular dilatation of the bile ducts, which may lead to a “beaded” appearance




# Signs and Symptoms

- A large number ( >50%) of patients present without symptoms
- Fatigue
- Pruritis
- Jaundice
- Rectal bleeding, diarrhea.
- RUQ pain







**Bhatti GI**  
CONSULTANTS, P.A.

# Types of PSC

- Classic PSC
- Small duct PSC



**Bhatti GI**  
CONSULTANTS, P.A.

# Diagnosis

- 1 . MRCP is preferred over endoscopic retrograde cholangiopancreatography (ERCP) to establish a diagnosis of PSC.
- 2 . Liver biopsy is not necessary to make a diagnosis in patients with suspected PSC based on diagnostic cholangiographic findings.
- 3 . Liver biopsy is recommended to make a diagnosis in patients with suspected small duct PSC or to exclude other conditions such as suspected overlap syndrome with autoimmune hepatitis, PBC



**Bhatti GI**  
CONSULTANTS, P.A.

# Serologic findings in patients with PSC


- Hypergammaglobulinemia – 30 percent
- Increased serum immunoglobulin M (IgM) levels – 40 to 50 percent
- Atypical perinuclear antineutrophil cytoplasmic antibodies (P-ANCA) – 30 to 80 percent
- Human leukocyte antigen DRw52a – 0 to 100 percent in various reports





# Normal ERCP and CBD



**Bhatti GI**  
CONSULTANTS, P.A.



**Bhatti GI**  
CONSULTANTS, P.A.




**Bhatti GI**  
CONSULTANTS, P.A.



**Bhatti GI**  
CONSULTANTS, P.A.



# ERCP image in PSC



**Bhatti GI**  
CONSULTANTS, P.A.

# Differential diagnosis of primary sclerosing cholangitis

- **Secondary sclerosing cholangitis**
- Cholangiocarcinoma
- **IgG4-associated cholangitis**
- Histiocytosis X
- Autoimmune hepatitis
- HIV syndrome
- Bile duct strictures
- Choledocholithiasis.
- **Primary biliary cirrhosis**
- Papillary tumors




# Small duct PSC Differential Diagnosis

- Liver biopsy is recommended to make a diagnosis in patients with suspected small duct PSC or to exclude other conditions such as suspected overlap with autoimmune hepatitis.
- Antimitochondrial autoantibody testing can help exclude ( PBC) primary biliary cirrhosis.
- Patients with PSC should be tested at least once for elevated serum immunoglobulin G4 (IgG4) levels.




# PSC





**Bhatti GI**  
CONSULTANTS, P.A.

# Histology




**Bhatti GI**  
CONSULTANTS, P.A.

# PBC



**Bhatti GI**  
CONSULTANTS, P.A.



| PBC                                | PSC                            |
|------------------------------------|--------------------------------|
| Interlobular bile duct destruction | Intra-/extrahepatic bile ducts |
| Prevalence: 0.6–40 per 100,000     | Prevalence: 0.2–14 per 100,000 |
| Gender: F>M, 10:1                  | Gender F<M, 1:2                |
| Age at onset: 50–60 years          | Age at onset: 30–40 years      |
| Smoking increases risk             | Smoking decreases risk         |
| >28 known risk genes               | >16 known risk genes           |
| Autoantibodies (AMA)               | Autoantibodies (ANCA?)         |
| Known T cell targets               | Unknown T cell targets         |

Shared hepatic features:

- Autoimmune hepatitis (~10%)
- Cholestatic liver cirrhosis
- Pruritus
- Fatigue



**Bhatti GI**  
CONSULTANTS, P.A.

# PSC and IBD

- Annual colon surveillance preferably with chromoendoscopy is recommended in PSC patients with colitis beginning at the time of PSC diagnosis.
- A full colonoscopy with biopsies is recommended in patients with PSC regardless of the presence of symptoms to assess for associated colitis at time of PSC diagnosis.
- Some advocate repeating the exam every 3–5 years in those without prior evidence of colitis.





# Medications

- Ursodeoxycholic acid



**Bhatti GI**  
CONSULTANTS, P.A.

# ENDOSCOPIC MANAGEMENT

- 1 . ERCP with balloon dilatation is recommended for PSC patients with dominant stricture and pruritus, and/or cholangitis, to relieve symptoms.
- 2 . PSC with a dominant stricture seen on imaging should have an ERCP with cytology, biopsies, and fluorescence *in-situ* hybridization (FISH), to exclude diagnosis of cholangiocarcinoma.
- 3 . PSC patients undergoing ERCP should have antibiotic prophylaxis to prevent post-ERCP cholangitis
- 4 . Routine stenting after dilation of a dominant stricture is not required, whereas short-term stenting may be required in patients with severe stricture.



# Complications of PSC

- Fat-soluble vitamin deficiencies (A, D, E, and K)
- Metabolic bone disease
- Dominant biliary strictures
- Cholangitis and cholelithiasis
- Cholangiocarcinoma
- Gallbladder cancer
- Hepatocellular carcinoma (in patients with cirrhosis)
- Colon cancer (in patients with concomitant ulcerative colitis)



# Liver Transplant

- Liver transplantation, when possible, is recommended over medical therapy or surgical drainage in PSC patients with decompensated cirrhosis, to prolong survival.
- Patients should be referred for liver transplantation when their Model for End-Stage Liver Disease (MELD) score exceeds 14.
- Outcomes for liver transplantation in PSC compare favorably to transplants for other indications,



# special circumstances in which liver transplantation may be indicated despite low MELD score

- Recurrent or refractory cholangitis
- Intractable pruritus
- Peripheral or hilar cholangiocarcinoma <3 cm in diameter (in the context of a clinical trial)



# CANCER SCREENING

- Gallbladder carcinoma and cholangiocarcinoma
- An annual ultrasound examination to detect mass lesions in the gallbladder.
- Ultrasound or magnetic resonance imaging (MRI) to look for evidence of cholangiocarcinoma every 6 to 12 months.
- Serum levels of the tumor marker cancer antigen (CA) 19-9 every 6 to 12 months to detect cholangiocarcinoma.
- Cholecystectomy in patients found to have a gallbladder polyp >8 mm (of note, some guidelines recommend cholecystectomy for gallbladder masses of any size
- Evaluation for cholangiocarcinoma in patients with deterioration of constitutional performance status or liver biochemical tests.

